Genetic analysis suggests high misassignment rates in clinical Alzheimer's cases and controls
Open accessAbstract
Genetic case-control association studies are often based on clinically ascertained cases and population or convenience controls. It is known that some of the controls will contain cases, as they are usually not screened for the disease of interest. However, even clinically assessed cases and controls can be misassigned. For Alzheimer's disease (AD), it is important to know the accuracy of the clinical assignment. The predictive accuracy of AD risk by polygenic risk score analysis has been reported in both clinical and pathologically confirmed cohorts. The genetic risk prediction can provide additional insights to inform classification of subjects to case and control sets at a preclinical stage. In this study, we take a mathematical approach and aim to assess the importance of a genetic component for the assignment of subjects to AD-positive and -negative groups, and provide an estimate of misassignment rates (MARs) in AD case/control cohorts accounting for genetic prediction modeling results. The derived formulae provide a tool to estimate MARs in any sample. This approach can also provide an estimate of the maximal and minimal MARs and therefore could be useful for statistical power estimation at the study design stage. We illustrate this approach in 2 independent clinical cohorts and estimate misdiagnosis rate up to 36% in controls unscreened for the APOE genotype, and up to 29% when E3 homozygous subjects are used as controls in clinical studies.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Cites
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336 · see citing works
Self-citationHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · see citing works
Self-citationStaging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357 · see citing works
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · see citing works
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
Qiu, C., Kivipelto, M., & von Strauss, E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/cqiu · Cited by 1,261 · see citing works
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 3× · see citing works
“3%) reported in [Beach et al. 2012], was when the clinical diagnosis was defined as clinically probable or possible AD, and neuropathologic AD definition was defined as “frequent neuritic plaque density score” and Braak neurofibrillary tangle stage V or VI.”
BackgroundInfluentialA survey of genetic human cortical gene expression
Myers, A. J., Gibbs, J. R., Webster, J. A., Rohrer, K., Zhao, A., Marlowe, L., Kaleem, M., Leung, D., Bryden, L., Nath, P., et al. (2007) · Nature Genetics · doi:10.1038/ng.2007.16 · Cited by 479 · see citing works
Self-citationCommon polygenic variation enhances risk prediction for Alzheimer’s disease
Escott-Price, V., Sims, R., Bannister, C., Harold, D., Vronskaya, M., Majounie, E., Badarinarayan, N., GERAD/PERADES, consortia, I., Morgan, K., et al. (2015) · Brain · doi:10.1093/brain/awv268 · Cited by 414 · see citing works
Self-citationThe National Alzheimer's Coordinating Center (NACC) Database: an Alzheimer disease database.
Beekly, D. L., Ramos, E. M., van Belle, G., Deitrich, W. D., Clark, A. D., Jacka, M. E., & Kukull, W. A. (2004) · PubMed · Cited by 345 · see citing works
Genetic Control of Human Brain Transcript Expression in Alzheimer Disease
Webster, J. A., Gibbs, J. R., Clarke, J., Ray, M., Zhang, W., Holmans, P., Rohrer, K., Zhao, A., Marlowe, L., Kaleem, M., et al. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2009.03.011 · Cited by 304 · see citing works
Self-citationCorneveaux, J. J., Myers, A. J., Allen, A. N., Pruzin, J. J., Ramirez, M., Engel, A., Nalls, M. A., Chen, K., Lee, W., Chewning, K., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq221 · Cited by 237 · see citing works
Self-citationPolygenic risk score analysis of pathologically confirmed Alzheimer disease
Escott‐Price, V., Myers, A., Huentelman, M. J., & Hardy, J. (2017) · Annals of Neurology · doi:10.1002/ana.24999 · Cited by 178 · see citing works
Self-citationModeling the prevalence and incidence of Alzheimer’s disease and mild cognitive impairment
Yesavage, J. A., O'Hara, R. M., KRAEMER, H. C., Noda, A. M., Taylor, J. L., Ferris, S. H., Gély-Nargeot, M.-C., Rosen, A. C., Friedman, L., Sheikh, J. I., et al. (2002) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00020-1 · Cited by 109 · see citing works
Monsell, S. E., Kukull, W. A., Roher, A. E., Maarouf, C. L., Serrano, G., Beach, T. G., Caselli, R. J., Montine, T. J., & Reiman, E. M. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1721 · Cited by 82 · see citing works
Polygenic Risk Score Analysis of Alzheimer's Disease in Cases without APOE4 or APOE2 Alleles
Escott‐Price, V., Myers, A., Huentelman, M. J., Shoai, M., & Hardy, J. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.46 · Cited by 52 · see citing works
Self-citationThe human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target
Petyuk, V., Chang, R. R., Ramirez‐Restrepo, M., Beckmann, N. D., Henrion, M., Piehowski, P., Zhu, K., Wang, S., Clarke, J., Huentelman, M. J., et al. (2018) · Brain · doi:10.1093/brain/awy215 · Cited by 39 · see citing works
Self-citationPhase 3 Trials of Solanezumab for Mild-To-Moderate Alzheimer's Disease
(2014) · New England Journal of Medicine · doi:10.1056/nejmx140041 · Cited by 18 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Reiman, E. M., Arboleda-Velasquez, J. F., Quiroz, Y. T., Huentelman, M. J., Beach, T. G., Caselli, R. J., Chen, Y., Su, Y., Myers, A. J., Hardy, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14279-8 · Cited by 473 · see citing works
Self-citationBerisha, V., & Liss, J. M. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01199-1 · Cited by 41 · see citing works
Genes, pathways and risk prediction in Alzheimer’s disease
Hardy, J., & Escott-Price, V. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz163 · Cited by 27 · see citing works
Self-citation
- Authors
- Escott-Price, V., Baker, E., Shoai, M., Leonenko, G., Myers, A. J., Huentelman, M., & Hardy, J.
- Affiliations
- Cardiff University (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- University of Miami (US)
- Corresponding author
- Hardy, John
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 77
- Pages
- 178-182
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2914685835
- Cited by
- 18
- References
- 17
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 1 · 2023: 5 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 1
- FWCI
- 1.59
- Type
- journal article
- Language
- en
- Open access
- green
- orca.cardiff.ac.uk
- Licence
- Locations
- Neurobiology of Aging (publishedVersion)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion, cc-by-nc-nd)
- Funders
- National Institutes of Health (R01-AG-034504)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease, polygenic risk score, APOE genotype, diagnostic accuracy, statistical power estimation, genetic risk prediction
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Diagnostic Errors, Female, Genotype, Humans, Male, Risk, Cohort Studies, Case-Control Studies, Genetic Association Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
